Skip to main content
. 2022 Jul 21;127(7):1270–1278. doi: 10.1038/s41416-022-01889-1

Fig. 5. Survival analyses (log-rank test) of the proposed pT3a/b subclassification in a pooled analysis combining all CRCs from the training cohort and both validation cohorts.

Fig. 5

a–d Disease-specific survival analysis of pT3a vs. pT3b CRCs within all pT3 tumours (a) and in pN0 (b), pN1/2 (c) and pM0 subgroups (d) of patients with pT3 tumours. e–h Disease-specific survival analysis of pT3a vs. pT3b CRCs compared to all pT stages in the overall cohort (e) and in pN0 (f), pN1/2 (g) and pM0 subgroups (h).